Keeley Funds Comments on Zoetis

Guru stock highlight

Author's Avatar
Aug 14, 2017

Zoetis (NYSE:ZTS) is an animal health company that was a spin off from Pfizer. The company reported very strong quarterly earnings and raised guidance for the full year. Early in the quarter, the company announced the acquisition of Nextvet, which strengthens their pipeline by adding an injectable pain platform to further diversify their animal health portfolio. Zoetis remains well positioned to continue to increase share in the livestock and companion animal markets while being insulated from the drug pricing and healthcare reform issues pressuring the human pharmaceutical companies.

From Keeley All Cap Value Fund second quarter 2017 shareholder commentary.